Computed tomography density changes of bone metastases after concomitant denosumab

ObjectiveTo evaluate bone density changes at the level of normal trabecular bone and bone metastases (BMs) after denosumab (DM) treatment in oncologic patients.Materials and methodsWe retrospectively evaluated 31 consecutive adult patients with histologically confirmed solid tumors with at least one newly diagnosed bone metastatic lesion detected at CT. Patients received treatment with DM, 120 mg subcutaneous every 28 days for at least 6 months. Bone density was determined at the level of BMs and at the level of normal trabecular bone of lumbar vertebrae using a region of interest (ROI)-based approach.ResultsA progressive increase in CT bone density was demonstrated at the level of normal trabecular bone at 6 months (18% +/- 5%) and 12 months (23% +/- 7%) after the treatment begins. BMs showed a significant increase in CT bone density (p < 0.05) as compared to baseline after 6 months (57% +/- 15%) and 12 months (1.06 +/- 0.25 times higher) after treatment.ConclusionWe have found that long-term treatment with DM increases bone density progressively in oncologic patients. This effect can be observed not only at the level of secondary lesions but also at the level of apparently normal trabecular bone and is more pronounced for osteolytic metastases.